Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Announces Agreement to Minimize Dilution from March 2025 Private Placement, Cancels Series A Warrants
Plus Therapeutics Inc. announced a significant private placement agreement with various purchasers, under which it issued 4,069,738 shares of common stock and prefunded warrants for up to 23,972,400 shares of common stock. Additionally, Series A Warrants for up to 280,421,380 shares and Series B Warrants for up to 1,261,896,210 shares were also part of the issuance. In an effort to minimize dilution, the company entered into a letter agreement with the purchasers to return a portion of the securities, cancel all Series A Warrants, and amend the Series B Warrants to reduce the number of shares issuable and adjust exercise ratios.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-142093), on June 17, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。